Dr. Wheadon joined the board of Vaxart in April 2021. Dr. Wheadon is a former senior executive of AstraZeneca plc, having recently retired as senior vice president (SVP), global regulatory affairs, patient safety and quality assurance. Dr. Wheadon has held many leadership roles in the healthcare sector, including: executive vice president, research and advocacy at the Juvenile Diabetes Research Foundation; SVP, scientific and regulatory affairs at PhRMA; SVP of global pharmaceutical regulatory and medical sciences at Abbott Laboratories; SVP of U.S. regulatory affairs at GlaxoSmithKline Pharmaceuticals; vice president and director CNS/GI Clinical Research at SmithKline Beecham Pharmaceuticals; and clinical research physician at Eli Lilly and Company. Dr. Wheadon has been integral to the successful development and approval of several important drugs for central nervous system diseases, diabetes, gastrointestinal disorders and diseases in other therapeutic areas. Dr. Wheadon holds a M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts. Dr. Wheadon currently serves on the board of Karuna Therapeutics Inc. and ConnectiveRx.
